| cardiovascular prevention | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Laufs, 2004 | cerivastatin vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| Laufs, 2004 | cerivastatin 0.4 mg (n=8) vs. placebo (n=7) | patients with heart failure NYHA
II-III caused by non-ischemic dilated
cardiomyopathy | double blind Parallel groups Sample size: 8/7 Primary endpoint: FU duration: mean 20 weeks |
|
| heart failure | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Laufs, 2004 | cerivastatin vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| Laufs, 2004 | cerivastatin 0.4 mg (n=8) vs. placebo (n=7) | patients with heart failure NYHA
II-III caused by non-ischemic dilated
cardiomyopathy | double blind Parallel groups Sample size: 8/7 Primary endpoint: FU duration: mean 20 weeks |
|
